Skip to main content

Table 4 Segmented regression analysis on the monthly cost of ACEIs/ARBs, ACEIs and ARBs

From: The impact of the ‘Better Care Better Value’ prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design

Variables β1(a) β2(b) β3(c) β4(d) β5(e) β6(f) β7(g)
ACEIs/ARBs 22072 (15546,28599) --- --- −287538 (−368885,-206192) −15970 (−21775,-10164) −266656 (−349379,-183932) −15019 (−22054,-7983)
ACEIs 6228.8 (4372, 8086) --- --- --- --- −286941 (−308447,-265435) −6094 (−7971,-4217)
ARBs 17030 (13449, 20611) --- --- −298044 (−357163, −238924) −15548 (−19712,-11384) --- −9839 (−14560,-5118)
  1. Regression coefficients (95 % confidence intervals) for the final model (the most parsimonious models); (a) baseline trend; (b) level change following BCBV policy; (c) trend change following BCBV policy; (d) level change following generic losartan availability; (e) trend change following generic losartan availability; (f) level change following generic perindopril availability; (g) trend change following generic perindopril availability; −--: indicates insignificant estimates at 0.05 level, after stepwise backward elimination; ACEIs: Angiotensin converting enzyme inhibitors; ARBs: Angiotensin receptor blockers